AgomAb Therapeutics (NASDAQ:AGMB) Shares Gap Up – Time to Buy?

AgomAb Therapeutics NV (NASDAQ:AGMB)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $12.82, but opened at $13.40. AgomAb Therapeutics shares last traded at $14.16, with a volume of 133,752 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Wall Street Zen cut shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. B. Riley Financial started coverage on shares of AgomAb Therapeutics in a research report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price target on the stock. HC Wainwright initiated coverage on shares of AgomAb Therapeutics in a research note on Monday, June 22nd. They set a “buy” rating and a $35.00 price objective on the stock. Piper Sandler assumed coverage on shares of AgomAb Therapeutics in a report on Tuesday. They set an “overweight” rating and a $60.00 price objective for the company. Finally, Cantor Fitzgerald assumed coverage on shares of AgomAb Therapeutics in a research note on Wednesday, August 19th. They issued an “overweight” rating for the company. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.50.

AgomAb Therapeutics Trading Up 9.7%

The firm’s 50 day moving average is $12.94.

AgomAb Therapeutics (NASDAQ:AGMB) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. Equities analysts anticipate that AgomAb Therapeutics NV will post -1.71 EPS for the current fiscal year.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.